Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.
January 18 2022 - 6:50AM
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
advancing a robust pipeline of oncology and neuroscience product
candidates that are designed to uniquely disrupt cellular signaling
dynamics, today announced the appointment of Diana F. Hausman,
M.D., Chief Medical Officer of Lengo Therapeutics (a wholly-owned
subsidiary of Blueprint Medicines Corporation), to its Board of
Directors. This appointment brings Immuneering’s Board to six
members.
“Diana has dedicated her career to creating new and better
possibilities for cancer patients, as a Board certified oncologist
with more than 20 years of clinical drug development experience at
both privately held and publicly traded companies. She brings an
important depth of expertise which will be invaluable as we
continue to advance our pipeline including our lead candidate,
IMM-1-104, a dual-MEK inhibitor for the treatment of RAS mutant
solid tumors,” stated Ben Zeskind, Ph.D., Co-Founder and Chief
Executive Officer of Immuneering. “She will fit right in with our
phenomenal, world-class board and her strengths will be highly
complementary. We look forward to Diana’s many contributions.”
“The preclinical data for IMM-1-104 is highly compelling, and
supports Immuneering’s unique deep-cyclic inhibition approach for
treating the many tumors that are driven by MAPK pathway
activation,” noted Dr. Hausman. “The earlier stage pipeline is also
very exciting, along with the translational bioinformatics platform
that yielded many of the counterintuitive, data-driven insights
underlying these programs. The Immuneering team is terrific. I am
honored to be working with them, and am eager to bring my specific
skills, insights and industry relationships to bear in order to
help the company achieve its goals.”
Dr. Hausman’s broad pharmaceutical industry experience includes
work with biologics, antibody-drug conjugates and targeted small
molecules in the fields of oncology (including immunotherapy),
hemostasis, hepatitis C, and Crohn's disease. Additionally, she is
well versed in all aspects of drug development, including
development and implementation of clinical strategy.
Since June 2021, Dr. Hausman has been the Chief Medical Officer
of Lengo Therapeutics, a biopharmaceutical company developing novel
precision medicines targeting driver mutations in oncology and now
a wholly-owned subsidiary of Blueprint Medicines Corporation. From
2016 to 2021, Dr. Hausman was Chief Medical Officer at Zymeworks
Inc., responsible for the development and implementation of global
clinical strategy for the company’s preclinical and clinical stage
products. Earlier, from 2009 to 2016, Dr. Hausman held various
positions at Oncothyreon Inc. (acquired by Seattle Genetics, Inc.),
most recently serving as Chief Medical Officer, overseeing the
Phase 1b and early Phase 2 clinical program for the HER2-targeted
small molecule, tucatinib. During her career, she has also held
positions of increasing responsibility at ZymoGenetics, Inc.
(acquired by Bristol Myers Squibb), Berlex, Inc. and Immunex
Corporation (acquired by Amgen Inc.).
Dr. Hausman received her internal medicine and specialty
training in hematology and medical oncology at the University of
Washington. She received her M.D. degree from the University of
Pennsylvania, Philadelphia, PA, and a Bachelor of Arts degree in
biology from Princeton University. She is an active member of both
the American Society of Hematology and American Society of Clinical
Oncology and is co-author of numerous papers, abstract and posters
which have been published in peer reviewed journals.
About Immuneering
Corporation Immuneering
is a biopharmaceutical company with an emerging pipeline focused on
improving patient outcomes across a spectrum of debilitating
oncologic and neurologic diseases by applying its deep knowledge of
translational bioinformatics to every stage of the drug development
process. Immuneering has more than a decade of experience in
translational bioinformatics and generating insights into drug
mechanisms of action and patient treatment responses. Building on
this experience, Immuneering has developed a disease-agnostic
platform that enables the company to utilize human data, novel
biology and chemistry, and translational planning to create and
advance its wholly owned pipeline. Immuneering’s current
development programs in oncology are focused on providing potential
treatments for patients with solid tumors caused by mutations of
oncologic signaling pathways, including the MAPK pathway.
Immuneering’s lead product candidate, IMM-1-104, is designed to be
a highly selective dual-MEK inhibitor that further disrupts KSR for
the treatment of advanced solid tumors in patients harboring RAS
mutant tumors. Additionally, Immuneering has six other oncology
programs in the discovery stage that are designed to target either
the MAPK or mTOR pathway, and two neuroscience programs in the
discovery stage.
Forward-Looking StatementsThis press release
includes certain disclosures that contain "forward-looking
statements," including, without limitation, statements regarding
Immuneering’s progress toward drugs targeting cancers driven by
alterations that activate the RAS/MAPK pathway, the treatment
potential of IMM-1-104, including in comparison to existing
treatments, the timing of regulatory filings for IMM-1-104 with the
FDA and commencement of clinical trials for IMM-1-104.
Forward-looking statements are based on Immuneering’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Factors that could cause
actual results to differ include, but are not limited to, the risks
inherent in oncology and neuroscience drug development, including
target discovery, target validation, lead compound identification,
lead compound optimization, preclinical studies and clinical
trials. These and other risks and uncertainties are described more
fully in the section titled "Risk Factors" in the Company’s most
recent Form 10-Q filed with the U.S. Securities and Exchange
Commission (SEC) as well as in Immuneering’s subsequent filings it
makes with the SEC. Forward-looking statements contained in this
announcement are made as of this date, and Immuneering undertakes
no duty to update such information except as required under
applicable law.
Corporate Contact:Rebecca Kusko,
Ph.D.Immuneering Corporation617-500-8080rkusko@immuneering.com
Investor Contact:Susan A. NoonanS.A. Noonan
Communications917-513-5303susan@sanoonan.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024